Want to see GH full AI Analyst Report?
Revenue by Segment
Analyzes income from different business units or product lines, highlighting which areas drive growth and profitability, and where strategic focus might be needed.
Guardant’s 2025 numbers reflect a reporting re‑split: the long‑running precision oncology franchise remains the engine with strong volume-driven growth, while Screening and Biopharma & Data surface as distinct, fast‑ramping contributors. Screening is scaling quickly and will drive substantial revenue growth but lower near‑term cash flow and blended ASPs due to heavy commercial investment; management expects this to continue in 2026. Critically, Guardant says the core oncology + biopharma business (ex‑screening) is on a path to free‑cash‑flow positivity, making screening the strategic growth—and near‑term profitability—lever.
GH Revenue by Segment
| Date | Oncology | Licensing and Other | Precision Oncology Testing | Development Services | Biopharma and Data | Screening |
|---|---|---|---|---|---|---|
| Jun 30, 2026 | $219.10M | $2.06M | $0.00 | $0.00 | $60.95M | $52.87M |
| Mar 31, 2026 | $204.95M | $2.14M | $0.00 | $0.00 | $52.98M | $41.59M |
| Dec 31, 2025 | $189.95M | $2.18M | $0.00 | $0.00 | $54.01M | $35.13M |
| Sep 30, 2025 | $184.40M | $1.95M | $0.00 | $0.00 | $54.73M | $24.11M |
| Jun 30, 2025 | $158.69M | $2.57M | $0.00 | $0.00 | $56.02M | $14.81M |
| Mar 31, 2025 | $150.56M | $1.86M | $0.00 | $0.00 | $45.38M | $5.68M |
| Dec 31, 2024 | $0.00 | $0.00 | $184.59M | $17.23M | $0.00 | $0.00 |
| Sep 30, 2024 | $0.00 | $0.00 | $180.60M | $10.87M | $0.00 | $0.00 |
| Jun 30, 2024 | $0.00 | $0.00 | $166.52M | $10.72M | $0.00 | $0.00 |
| Mar 31, 2024 | $0.00 | $0.00 | $156.23M | $12.26M | $0.00 | $0.00 |
| Dec 31, 2023 | $0.00 | $0.00 | $142.19M | $12.87M | $0.00 | $0.00 |
| Sep 30, 2023 | $0.00 | $0.00 | $133.42M | $9.61M | $0.00 | $0.00 |
| Jun 30, 2023 | $0.00 | $0.00 | $125.24M | $11.91M | $0.00 | $0.00 |
| Mar 31, 2023 | $0.00 | $0.00 | $113.39M | $15.32M | $0.00 | $0.00 |
| Dec 31, 2022 | $0.00 | $0.00 | $113.80M | $13.09M | $0.00 | $0.00 |
| Sep 30, 2022 | $0.00 | $0.00 | $102.05M | $15.35M | $0.00 | $0.00 |
| Jun 30, 2022 | $0.00 | $0.00 | $92.06M | $17.08M | $0.00 | $0.00 |
| Mar 31, 2022 | $0.00 | $0.00 | $84.14M | $11.96M | $0.00 | $0.00 |
| Dec 31, 2021 | $0.00 | $0.00 | $88.71M | $19.40M | $0.00 | $0.00 |
| Sep 30, 2021 | $0.00 | $0.00 | $79.27M | $15.51M | $0.00 | $0.00 |
| Jun 30, 2021 | $0.00 | $0.00 | $72.60M | $19.50M | $0.00 | $0.00 |
| Mar 31, 2021 | $0.00 | $0.00 | $63.73M | $14.94M | $0.00 | $0.00 |
| Dec 31, 2020 | $0.00 | $0.00 | $64.70M | $13.61M | $0.00 | $0.00 |
| Sep 30, 2020 | $0.00 | $0.00 | $60.38M | $14.19M | $0.00 | $0.00 |
| Jun 30, 2020 | $0.00 | $0.00 | $50.99M | $15.34M | $0.00 | $0.00 |
| Mar 31, 2020 | $0.00 | $0.00 | $60.25M | $7.26M | $0.00 | $0.00 |
| Dec 31, 2019 | $0.00 | $0.00 | $57.41M | $5.48M | $0.00 | $0.00 |
| Sep 30, 2019 | $0.00 | $0.00 | $52.15M | $8.70M | $0.00 | $0.00 |
| Jun 30, 2019 | $0.00 | $0.00 | $42.06M | $11.91M | $0.00 | $0.00 |
| Mar 31, 2019 | $0.00 | $0.00 | $28.84M | $7.82M | $0.00 | $0.00 |